157 related articles for article (PubMed ID: 32588830)
1. [Modeling of drug-drug interactions between omeprazole and erythromycin with cytochrome P450 3A4 in vitro assay].
Koroleva PI; Kuzikov AV; Masamrekh RA; Filimonov DA; Dmitriev AV; Zaviyalova MG; Rikova SM; Shich EV; Makhova AA; Bulko TV; Gilep AA; Shumyantseva VV
Biomed Khim; 2020 May; 66(3):241-249. PubMed ID: 32588830
[TBL] [Abstract][Full Text] [Related]
2. In vitro interactions of abiraterone, erythromycin, and CYP3A4: implications for drug-drug interactions.
Masamrekh RA; Kuzikov AV; Haurychenka YI; Shcherbakov KA; Veselovsky AV; Filimonov DA; Dmitriev AV; Zavialova MG; Gilep AA; Shkel TV; Strushkevich NV; Usanov SA; Archakov AI; Shumyantseva VV
Fundam Clin Pharmacol; 2020 Feb; 34(1):120-130. PubMed ID: 31286572
[TBL] [Abstract][Full Text] [Related]
3. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.
Yamazaki H; Shimada T
Drug Metab Dispos; 1998 Nov; 26(11):1053-7. PubMed ID: 9806945
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Cytochrome P450 Enzyme and Drug-Drug Interaction Potential of Acid Reducing Agents Used in Management of CDK Inhibitors for Breast Cancer Chemotherapy.
Patil PH; Jagadish PC; Fatima F; Birangal S; Shenoy GG; Rao M; Farooqui J; Rastogi H; Sharma T; Pinjari J
Curr Drug Metab; 2022; 23(2):137-149. PubMed ID: 35184709
[TBL] [Abstract][Full Text] [Related]
5. Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilation.
Lemahieu WP; Maes BD; Verbeke K; Vanrenterghem Y
Kidney Int; 2005 Mar; 67(3):1152-60. PubMed ID: 15698457
[TBL] [Abstract][Full Text] [Related]
6. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs.
McConn DJ; Lin YS; Allen K; Kunze KL; Thummel KE
Drug Metab Dispos; 2004 Oct; 32(10):1083-91. PubMed ID: 15377640
[TBL] [Abstract][Full Text] [Related]
7. A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors.
Schueller O; Willson A; Singh N; Lohmer L; Alabanza A; Patel J
Clin Pharmacol Drug Dev; 2022 Jul; 11(7):795-806. PubMed ID: 35230741
[TBL] [Abstract][Full Text] [Related]
8. Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug-Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole.
Le Merdy M; Tan ML; Sun D; Ni Z; Lee SC; Babiskin A; Zhao L
Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):41-51. PubMed ID: 33064292
[TBL] [Abstract][Full Text] [Related]
9. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
[TBL] [Abstract][Full Text] [Related]
11. Inactivation kinetics and residual activity of CYP3A4 after treatment with erythromycin.
Ishikawa Y; Akiyoshi T; Imaoka A; Ohtani H
Biopharm Drug Dispos; 2017 Oct; 38(7):420-425. PubMed ID: 28425104
[TBL] [Abstract][Full Text] [Related]
12. Drug-drug interactions and cooperative effects detected in electrochemically driven human cytochrome P450 3A4.
Sadeghi SJ; Ferrero S; Di Nardo G; Gilardi G
Bioelectrochemistry; 2012 Aug; 86():87-91. PubMed ID: 22480862
[TBL] [Abstract][Full Text] [Related]
13. Predicting drug-drug interactions by electrochemically driven cytochrome P450 3A4 reactions.
Shumyantseva VV; Koroleva PI; Bulko TV; Sergeev GV; Usanov SA
Drug Metab Pers Ther; 2022 Sep; 37(3):241-248. PubMed ID: 34860476
[TBL] [Abstract][Full Text] [Related]
14. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
Meyer UA
Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
16. No effect of lipoic acid on catalytic activity of cytochrome P450 3A4.
Makhova AA; Shikh EV; Bulko TV; Gilep AA; Usanov SA; Shumyantseva VV
Drug Metab Pers Ther; 2020 Jul; 35(3):. PubMed ID: 32712589
[TBL] [Abstract][Full Text] [Related]
17. In vitro inhibition of methadone and oxycodone cytochrome P450-dependent metabolism: reversible inhibition by H2-receptor agonists and proton-pump inhibitors.
Moody DE; Liu F; Fang WB
J Anal Toxicol; 2013 Oct; 37(8):476-85. PubMed ID: 23857299
[TBL] [Abstract][Full Text] [Related]
18. Effect of CYP3A inhibition on vesnarinone metabolism in humans.
Wandel C; Lang CC; Cowart DC; Girard AF; Bramer S; Flockhart DA; Wood AJ
Clin Pharmacol Ther; 1998 May; 63(5):506-11. PubMed ID: 9630823
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin.
Paine MF; Wagner DA; Hoffmaster KA; Watkins PB
Clin Pharmacol Ther; 2002 Nov; 72(5):524-35. PubMed ID: 12426516
[TBL] [Abstract][Full Text] [Related]
20. Improving the Efficiency of Electrocatalysis of Cytochrome P450 3A4 by Modifying the Electrode with Membrane Protein Streptolysin O for Studying the Metabolic Transformations of Drugs.
Koroleva PI; Gilep AA; Kraevsky SV; Tsybruk TV; Shumyantseva VV
Biosensors (Basel); 2023 Apr; 13(4):. PubMed ID: 37185532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
